From: Multiple Sclerosis News Today By: Marisa Wexler MS Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments
Implications abound for historic leader Amgen and newer companies with paradigm-shifting SGLT2 inhibitors (AstraZeneca [Farxiga], Vifor/Janssen [Invokana], Eli Lilly/Boehringer Ingelheim
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be
The new addition ties Spherix’s unique approach to syndicated research to a highly dynamic market, filling the white space for
From: Endpoints News By: Beth Snyder Bulik Five months after the approval of Biogen’s Aduhelm, the bad news just
From: Multiple Sclerosis News Today By: Marisa Wexler MS Ocrevus (ocrelizumab) continues to be the most commonly prescribed therapy for
New patient-level data show that newer market entrants, such as BMS’ Zeposia and Novartis’ Kesimpta, are gaining traction in the
New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well
Authors: Meghan Staudt, Skylar Malone, Tucker Hurtado BACKGROUND: Disparities in kidney care are widespread and gaining more attention. This research
What the Aduhelm manufacturers and others with agents in the pipeline can learn from early launch metrics EXTON, Pa., October
From: FiercePharma By: Angus Liu Tuesday, AbbVie said the FDA has green-lighted its Qulipta, or atogepant, for prevention of episodic migraine.
One month post launch, Spherix data indicates that Aduhelm (aducanumab-avwa) awareness easily outpaces other key performance indicators, including degree of
